[A21-15] Upadacitinib (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V
Last updated 15.07.2021
Project no.:
A21-15
Commission:
Commission awarded on 01.03.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Muscles, bones and joints
Adult patients with active psoriatic arthritis
Patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy: hint of minor added benefit. Patients who have had an inadequate response or who have been intolerant to a prior therapy with biologic disease-modifying antirheumatic drugs (bDMARDs): added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A20-08 | Upadacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-16 | Upadacitinib (ankylosing spondylitis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-81 | Upadacitinib (psoriatic arthritis) - Addendum to Commission A21-15 | Commission completed |
| A23-38 | Upadacitinib (Crohn disease) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-116 | Upadacitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-91 | Upadacitinib (ulcerative colitis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-92 | Upadacitinib (axial spondyloarthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2021.07.15 A G-BA decision was published.